<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05091060</url>
  </required_header>
  <id_info>
    <org_study_id>R-Tinnitus-Pilot</org_study_id>
    <nct_id>NCT05091060</nct_id>
  </id_info>
  <brief_title>A Pilot Evaluation of the Effect of the Erchonia® HLS™ for the Relief of Tinnitus Symptoms</brief_title>
  <official_title>A Pilot Evaluation of the Effect of the Erchonia® HLS™ for the Relief of Tinnitus Symptoms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erchonia Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Erchonia Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to see if applying red low-level laser light can help to reduce tinnitus&#xD;
      symptoms&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this pilot study is to determine the effectiveness of the Erchonia® HLS™,&#xD;
      manufactured by Erchonia Corporation (the Company), in providing temporary relief of tinnitus&#xD;
      symptoms in adults 18 years and older.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 10, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Score on the Tinnitus Handicap Inventory (THI).</measure>
    <time_frame>Baseline and 8 week</time_frame>
    <description>The Tinnitus Handicap Inventory (THI) is a 25-item questionnaire to assess how tinnitus affects an individual's life. Each question is responded to as 'yes' (4 points); 'sometimes' (2 points) or 'no' (0 points). The individual scores for the 25 questions are added to get a total THI score from 0 to 100. The higher the total THI score, the greater the negative impact tinnitus has on the individual's life. Change in total THI score is calculated as total THI score after the one week procedure administration phase minus total THI score at baseline. A positive (+) change in total THI score indicates the negative impact of tinnitus on the individual's everyday life has worsened. A negative (-) change indicates the negative impact of tinnitus on the individual's everyday life has improved (lessened).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">5</enrollment>
  <condition>Tinnitus</condition>
  <arm_group>
    <arm_group_label>Erchonia HLS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>635 nanometers (nm) laser application</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Erchonia HLS</intervention_name>
    <description>56 procedure administrations with the Erchonia® HLS™ administered by the subject at home: daily procedure administrations for 8 weeks.</description>
    <arm_group_label>Erchonia HLS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjective tinnitus&#xD;
&#xD;
          -  Tonal tinnitus.&#xD;
&#xD;
          -  Constant tinnitus on-going at least half the time over at least the past 6 months.&#xD;
&#xD;
          -  Willing to abstain from other tinnitus-related treatments except prior hearing aid use&#xD;
             throughout the study duration.&#xD;
&#xD;
          -  Willing and able to refrain from activities or work involving excessive noise exposure&#xD;
             without the use of effective hearing protection throughout study participation.&#xD;
&#xD;
          -  18 years of age or older&#xD;
&#xD;
          -  Primary language is English&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Objective tinnitus&#xD;
&#xD;
          -  Atonal, pulsatile, intermittent, or occasional tinnitus&#xD;
&#xD;
          -  Severe or profound hearing loss in one or both ears&#xD;
&#xD;
          -  Current or prior surgically removed acoustic neuroma&#xD;
&#xD;
          -  Consistent use of any of the following drugs known to cause or increase tinnitus&#xD;
             (primarily ototoxins) within the past 30 days:&#xD;
&#xD;
        NSAIDS (motrin, naproxen, relafen, etc) aspirin (exceeding 300mg per day) and other&#xD;
        salicylates Lasix and other &quot;loop&quot; diuretics &quot;mycin&quot; antibiotics such as vancomycin quinine&#xD;
        and related drugs Chemotherapy agents such as cis-platin&#xD;
&#xD;
          -  Acute or chronic vertigo/dizziness&#xD;
&#xD;
          -  Ménière's disease&#xD;
&#xD;
          -  Prior stapendectomy&#xD;
&#xD;
          -  Prior mastoidectomy&#xD;
&#xD;
          -  Auditory nerve tumor (acoustic neuroma), current or surgically removed in the past&#xD;
&#xD;
          -  Active infection/wound/external trauma to the areas to be treated with the laser&#xD;
&#xD;
          -  Medical, physical or other contraindications for, or sensitivity to, light therapy&#xD;
&#xD;
          -  Pregnant, breast feeding, or planning pregnancy prior to the end of study&#xD;
             participation&#xD;
&#xD;
          -  Developmental disability or cognitive impairment that in the opinion of the&#xD;
             investigator would preclude adequate comprehension of the informed consent form and/or&#xD;
             ability to record the necessary study measurements&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Kathy Amos</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 12, 2021</study_first_submitted>
  <study_first_submitted_qc>October 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2021</study_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tinnitus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

